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ABSTRACT 
Standard clinical parameters fail to accurately differentiate indolent from aggressive prostate 
cancer. Our previous studies showed that immunohistochemical testing for Ki-67 improved 
prediction of prostate cancer death in a previous cohort of conservatively treated clinically 
localized prostate cancer. However there is a need for validation of usage with whole biopsy 
sections rather than tissue micro-arrays for use in routine diagnostics. 
Prostate cancer biopsy cases were identified in the UK, between 1990 and 2003, treated 
conservatively. Tumor extent and prostate-specific antigen (PSA) serum measurements were 
available. Biopsy cases were centrally reviewed by three uropathologists and Gleason 
conformed to contemporary ISUP 2014 criteria. Follow-up was through cancer registries up 
until 2012. Deaths were divided into those from prostate cancer and those from other 
causes. The percentage of Ki-67 in tumor cells was evaluated by immunohistochemistry on 
whole biopsy sections and was available for 756 patients. This percentage was used in analysis 
of cancer specific survival using a Cox proportional hazards model. 
In univariate analysis, the interquartile hazard ratio (HR) (95% confidence intervals) for 
continuous Ki-67 was 1.68 (1.49, 1.89), χ₁²=47.975, P<0.001. In grade groups 1 and 2, 
continuous Ki-67 was a statistically significant predictor of time to death from prostate cancer, 
HR (95% CI) =1.97 (1.34, 2.88), χ₁²=9.017, p=0.003. In multivariate analysis, continuous Ki-
67 added significant predictive information to that provided by grade groups, extent of disease 
and serum PSA, HR (95% CI) =1.34 (1.16, 1.54), Δχ₁²=13.703, P<0.001. 
We now advocate the introduction of Ki-67 as a viable and practicable prognostic biomarker in 
clinical practice. The association of Ki-67 with mortality was highest in grade groups 1 and 2, 
showing that Ki-67 can be used as a routine biomarker in patients being considered for active 
surveillance.  
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INTRODUCTION  
Prostate cancer remains the most common non-cutaneous malignancy in men. However many 
patients do not require radical treatment and will die from unrelated causes. Consequently a 
significant proportion of patients undergo radical treatment without need ((1, 2). Conversely, 
some patients will fail treatments notwithstanding the use of combined modality approaches 
(3). Therefore decision making in early prostate cancer remains difficult even using current the 
clinical parameters of serum PSA, routine histopathology, imaging and patient age and 
performance status.   
In spite of extensive research, few molecular markers have been translated into routine use in 
genito-urinary oncology. Any new biomarker must give further predictive ability beyond that 
available by using current known, easily measured parameters, and the data must differentiate 
patients into groups for which different options can be selected from active surveillance to 
radical treatment.  
The most promising immunohistochemical biomarker identified for prostate cancer is Ki-67, a 
cell proliferation marker, expressed in G1, S, G2 and M phases of the cell cycle being absent in 
resting cells (G0). As the grading system in prostate cancer is pattern based and does not 
consider the proliferation rate of the cells, it is possible that measuring the cell proliferation rate 
in prostate tumors could yield additional prognostic information. Ki-67 has been shown to be 
an independent predictor of prostate cancer outcome in a large number of studies on systematic 
review (4).  
Our previous work, on the Trans-Atlantic Prostate Group cohort of conservatively managed 
prostate cancers diagnosed by transurethral resection of the prostate and needle biopsies showed 
that Ki-67 was an independent prognostically significant marker when PSA, Gleason score, and 
tumor extent were also considered (5, 6). However, this cohort included many transurethral 
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resection of the prostate patients, and biopsy patients were often sub-optimally sampled. Also 
these and other studies utilize tissue micro arrays and do not reflect the methods which will be 
used in routine pathology laboratories to assess Ki-67.  
Our hypothesis was that immunohistochemical assessment of  Ki-67, in a conservatively treated 
cohort, would be of independent prognostic value with prostate cancer death at the end point, 
using a methodology which could be directly translated to routine pathology laboratories and 
thus into clinical use. 
MATERIALS AND METHODS 
Patients 
Cases of prostate cancer were identified from three cancer registries in Great Britain. Within 
each region, collaborating hospitals were sought and cases from these hospitals were reviewed. 
Men were included in this study if they were under age 76 years at the date of diagnosis and 
had clinically localised prostate cancer diagnosed by needle biopsy between 1990 and 2003 
inclusively. The median date of diagnosis was May 2002. Patients treated by radical 
prostatectomy or radiation therapy within 6 months of diagnosis were excluded. In addition, 
those with objective evidence of metastatic disease (by bone scan, X-ray, radiograph, CT scan, 
MRI, bone biopsy, lymph node biopsy and pelvic lymph node dissection) or clinical indications 
of metastatic disease (including pathologic fracture, soft-tissue metastases, spinal compression, 
or bone pain), or a PSA measurement over 100 ng ml/1 at or within 6 months of diagnosis were 
also excluded. Men who had hormone therapy before the diagnostic biopsy were also excluded, 
because of the influence of hormone treatment on Gleason pattern. We also excluded men who 
died within 6 months of diagnosis, or had less than 6 months of follow-up. Follow-up was 
conducted through the cancer registries and the cut-off date was 31 December 2012. Deaths 
were divided into those from prostate cancer and those from other causes, according to World 
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Health Organisation standardised criteria (WHO, 2010). National ethics approval was obtained 
from the Northern Multicenter Research Ethics Committee, followed by local ethics committee 
approval at each of the collaborating hospitals. 
Histology 
Original histological specimens from the diagnostic procedure were requested and centrally 
reviewed by a panel of three expert urological pathologists to confirm the diagnosis of 
adenocarcinoma and to reassign Gleason score using of a contemporary and consistent 
interpretation of the Gleason scoring system (7, 8) and reclassified into grade groups (8).  
KI-67 immunohistochemistry 
Diagnostic formalin-fixed paraffin-embedded needle biopsy tissue blocks and slides were 
requested. Biopsies showing the highest Gleason grade were selected. Corresponding sections 
were immunoassayed for Ki-67 using MIB-1 antibody, DAKO, Carpinteria, CA, USA, and 
attempted to reduce pre analytical variables by following recommendations used in the 
assessment of Ki-67 in breast cancer by using the recommended methods and platforms (9). 
Briefly, cells were scored in a semi-quantitative manner, by an expert prostatic pathologist, and 
the mean percentage of positive cells was estimated as the proportion of Ki-67 stained 
malignant cells, in a manner similar to that used in routine pathology departments for the 
assessment of proliferation index in other organs (9, 10). Corresponding H&E slides were 
simultaneously reviewed. All nuclear immunostaining was recorded as positive and was clearly 
either strongly positive or negative. Normal tonsil was used as a positive control. The technique 
was designed to be robust for any pathology laboratory with experience in 
immunohistochemistry and allow results to be directly comparable to our previous work.  
Statistical analysis 
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Univariate and multivariate analysis was performed using a Cox proportional hazards model 
with the primary end point of analysis defined as death from prostate cancer. Observations 
stopped either on the date of death from other causes or on the date of last follow-up. Covariates 
included were age at diagnosis, grade groups, Ki-67 average, baseline PSA value (defined as 
last pre-diagnostic PSA measurement within 6 months before diagnosis), extent of disease 
(percentage of positive cores). Receiver operating characteristic curve analysis was performed 
at ten-year survival to assess the predictive cut-off value for Ki-67 expression used to analyse 
Ki-67 as a binary variable. All p-values were two-sided with significance set at α < 0.05. 
Statistical analyses were performed using R (version 3.4.3, The R Foundation for Statistical 
Computing, Vienna, Austria). 
RESULTS 
Cohort characterization  
A total of 756 patients were available for analysis. Out of them, 294 patients received no initial 
therapy, while 462 received early hormonal therapy only as an initial treatment. The mean, 
median and interquartile range of patient age, grade groups, serum PSA and extent of disease 
is shown in Table 1. Follow-up for prostate cancer death was until 31 December 2012 with 145 
(20%) patients who died from their cancer. The median follow-up time was 9.6 years (IQR: 
11.2-6.6). 
Ki-67 expression 
The mean percentage of Ki-67 was 5%, 53 (7%) scored as less than 1%, 429 (57%) as between 
2 and 5%, 175 (23%) as between 6 and 10% and 99 (13%) as more than 10 (Figure 1 and 
Supplementary Figure). The majority of deaths n=80 (55%) were in the high Ki-67 groups 
(>5%, n=274). The Receiver Operating Characteristics curve analysis (AUC=0.685, 95% CI: 
0.637-0.738) identified 5% as the most predictive cut-off value for Ki-67 expression with a 
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sensitivity of 60% and a specificity of 69%. This cut-off was subsequently used in univariate 
and multivariate analysis (Figure 2). 
Univariate analysis 
In univariate analysis, grade groups, PSA, extent of disease and Ki-67 were all significant 
predictors of prostate cancer death (Ki-67: HR = 1.68, 95% CI: 1.49-1.89), but not the age of 
patient (Table 2). Kaplan–Meier cancer specific survival curves for Ki-67 in 2 groups (≤5 or 
>5%) and showed significant difference between the two groups with an HR=2.65 (95% CI 
(1.91-3.69), log-rank test=33.46, p=7.3*10-09), Figure 3. Ki-67 was stratified by grade groups 
using Forest plot graphing (Figure 4).  It was found that the most predictive Ki-67 information 
was in grade groups 1 and 2 compared to the other groups (HR = 1.1, 95% CI: 1.04-1.16).  
Multivariate analysis 
In multivariate analysis, continuous and dichotomous Ki-67 variables added significant 
predictive information to that provided by grade groups and PSA alone (continuous Ki-67: HR 
= 1.34, 95% CI: 1.16, 1.54, Ki-67 5%: HR = 1.79, 95% CI: 1.27, 2.53). The covariates extent 
of disease and PSA were slightly less informative (Table 2). 
DISCUSSION 
The growing evidence concerning prostate cancer over-diagnosis and over-treatment 
emphasizes the need for accurate disease aggressiveness stratification (2). Owing to limitations 
of standard clinicopathological and biological parameters, there is an unmet need for robust 
biomarkers that may assist clinicians in deciding therapeutic strategy. 
Ki-67 is an attractive biomarker from a technical perspective due to its universal use and 
reproducible interpretation compared to other prostatic tissue biomarkers (11). Indeed, it is 
widely used in routine practice, affordable by academic and non-academic histopathology 
Ki-67 a prognostic marker in prostate cancer 
8 
 
departments, and easy to measure in a semi-quantitative manner. Immunochemistry has the 
advantage over other molecular techniques that it is easily applied to paraffin-embedded tissue 
and has a very low ‘failure’ rate, unlike fluorescence. 
Interestingly, results of immunohistochemical analysis of a single marker of cell proliferation, 
Ki-67, could correlate with those of a commercially available cell-cycle progression score 
(Prolaris®), a molecular test that evaluates RNA signature of several cell-cycle progression 
genes, as one of the cell-cycle progression genes codes for Ki-67 (12). If this hypothesis is 
validated, Ki-67 immunohistochemistry, with easier and broader worldwide implementation, 
well-established analytical performance, and reduced costs could help select patients for those 
the molecular test is relevant. 
Several studies have reported Ki-67 as an independent prognostic factor for prostate cancer. 
Nevertheless, there is a considerable heterogeneity among studies, including different 
endpoints, cohort types, sample sizes and cut-offs. The studies with cancer specific survival as 
an endpoint are compared in Table 3 (5, 6, 13-20).  
To our knowledge, our multicentre study is the largest to assess the prognostic impact of Ki-67 
in a cohort of diagnostic biopsies. In our previous cohort including conservatively managed 
patients, we demonstrated the discriminatory value of Ki-67 on transurethral resection of the 
prostate and needle biopsies (5, 6). However, this current cohort is larger, clinically more 
contemporary with Gleason grade reviewed according to last ISUP recommendations (21) and 
confirmed our first results. 
In this study, we performed Ki-67 on needle biopsies instead of radical prostatectomies or 
transurethral resection of the prostate specimens to approach conditions for clinical decision 
before any treatment. The assessment of Ki-67 on the whole slides rather than tissue micro 
arrays reflects routine use and avoids potential bias due to tumor heterogeneity. Indeed, studies 
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comparing the assessment of Ki-67 on tissue micro arrays and on whole slides recommended 
the use of the latter (22, 23).  
The Ki-67 cut-off varies from a study to another. In our series, we identified 5% Ki-67 as the 
most relevant cut-off given the results of our cut-point analysis (Receiver Operating 
Characteristics curve). This cut-off aligns with the most frequently used level, fixed around 5-
10% (4, 5, 18, 24) and the difference may be explained by the constitution of the cohort, the 
material or the method of assessment. In addition, Kaplan-Meier plots confirmed robust curve 
separation between low and high Ki-67 groups at 5% cut-off. 
For the first time, we report a subgroup analysis of Ki-67 prognostic impact in grade groups. 
Ki-67 was the most discriminatory in grade groups 1 and 2 compared to higher grade groups 
(Forest Plot). These low-grade groups with the best prognosis are frequently included in active 
surveillance studies (25). For these patients, Ki-67 expression could help discriminate the most 
aggressive from the majority of indolent cancers. 
The weaknesses of our study include its retrospective nature and the use of cases dating from 
1990 to 2003. Nevertheless, only long follow-up time enables appropriate assessment of cancer 
specific survival that was our endpoint. Metastasis free survival would have been a useful 
addition that is missing in our study. However, cancer specific survival is a major endpoint for 
any biomarker and is reproducible to compare studies. In needle biopsies cohort, the amount of 
cancer available in needle biopsies can be limited that could impact tumor representativeness 
and the assessment of multifocality. The immunohistochemistry itself has several limitations 
including the antibody, preanalytic and analytic steps lowered by its worldwide use in several 
other tumors and its reproducible interpretation (10).  
Ki-67 was mostly assessed by one pathologist. However, the inter-observer concordance in Ki-
67 assessment is good and could be further improved by the use of cut-offs (10). In addition, 
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visual scoring of Ki-67 and corresponding H&E slide was used instead of digital scoring as 
inflammation and high grade PIN in prostate biopsies are frequent pitfalls. In particular, 
inflammatory cells are frequently stained by Ki-67 immunohistochemistry and included in 
digital analysis. In addition, the two different approaches were compared in prostate cancer 
with a high inter-correlation agreement (26). 
In conclusion, Ki-67 immunoexpression independently predicted prostate cancer patient 
outcome, adjusted for standard clinico-pathological parameters, in a cohort of diagnostic 
biopsies. If incorporated into routine practice, this assessment might assist clinicians in 
discriminating the most aggressive prostate cancer, improving treatment selection especially in 
low-grade cancer. Nevertheless, owing to the limitations of this study, a prospective validation 
of our findings in independent series is required to confirm its clinical utility. 
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FIGURE LEGENDS: 
Figure 1. Distribution of Ki-67% staining in cases, n=756 
Figure 2. Survival Receiver Operating Characteristics curve at 10 years. The sensitivity (95% 
CI) and specificity (95% CI) were reported for a cut-off value of 2 (black square), 5 (black 
circle) and 10 (black triangle) of the Ki-67. All 95% confidence intervals (CI) were based on 
1000 bootstrap replicates. 
Figure 3. Kaplan–Meier estimates of prostate cancer death according to Ki-67 (negative: ≤5 
and positive: >5) at10-year death rate from prostate cancer. 
Figure 4. Forest plot graphing the Ki-67 Hazard Ratio in different grade groups. 
Supplementary Figure: HES and corresponding Ki67 immunohistochemistry for prostate 
biopsies x20. A: Gleason 7 (4+3), B: Ki67 <1%, C: Gleason 7 (3+4), D: Ki67 = 2%, E: Gleason 
6 (3+3), E: Ki67 = 7%, G: Gleason 9 (4+5), H: Ki67 = 40%. 
 
